Vaxcyte, Inc. (NASDAQ:PCVX) CFO Andrew Guggenhime Sells 8,000 Shares

Vaxcyte, Inc. (NASDAQ:PCVX) CFO Andrew Guggenhime sold 8,000 shares of Vaxcyte stock in a transaction dated Thursday, April 18th. The stock was sold at an average price of $61.27, for a total value of $490,160.00. Following the completion of the transaction, the chief financial officer now owns 95,679 shares in the company, valued at $5,862,252.33. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Andrew Guggenhime also recently made the following trade(s):

• On Monday, March 18th, Andrew Guggenhime sold 8,000 shares of Vaxcyte stock. The shares were sold at an average price of $69.02, for a total value of $552,160.00.

Vaxcyte Trading Down 1.2 %

PCVX opened at $60.88 on Wednesday. The stock’s 50 day simple moving average is $68.83 and its 200-day simple moving average is $61.29. The stock has a market cap of $6.62 billion, a PE ratio of -14.74 and a beta of 0.89. Vaxcyte, Inc. has a 1 year low of $41.57 and a 1 year high of $82.04.

Vaxcyte (NASDAQ:PCVX) last posted its quarterly earnings results on Tuesday, February 27th. The company reported ($1.82) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.89) by ($0.93). During the same period in the previous year, the business posted ($0.73) EPS. Equities analysts forecast that Vaxcyte, Inc. will post -4.18 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on PCVX shares. Needham & Company LLC reiterated a “buy” rating and set a $95.00 price target on shares of Vaxcyte in a report on Wednesday, April 10th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Vaxcyte in a research note on Friday, January 12th. Finally, Bank of America boosted their price objective on shares of Vaxcyte from $67.00 to $80.00 and gave the stock a “buy” rating in a report on Tuesday, January 2nd. Four equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average price target of $78.50.

Institutional Trading of Vaxcyte

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Raymond James & Associates lifted its stake in Vaxcyte by 28.7% during the first quarter. Raymond James & Associates now owns 66,332 shares of the company’s stock worth $4,531,000 after purchasing an additional 14,779 shares during the period. Allspring Global Investments Holdings LLC raised its holdings in shares of Vaxcyte by 109.7% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 47,388 shares of the company’s stock worth $3,237,000 after buying an additional 24,785 shares in the last quarter. Banque Cantonale Vaudoise lifted its position in shares of Vaxcyte by 96.7% during the 1st quarter. Banque Cantonale Vaudoise now owns 1,184 shares of the company’s stock worth $81,000 after buying an additional 582 shares during the period. PNC Financial Services Group Inc. boosted its stake in Vaxcyte by 25.3% in the 4th quarter. PNC Financial Services Group Inc. now owns 6,986 shares of the company’s stock valued at $439,000 after buying an additional 1,411 shares in the last quarter. Finally, Vanguard Group Inc. grew its position in Vaxcyte by 2.0% in the fourth quarter. Vanguard Group Inc. now owns 8,452,371 shares of the company’s stock valued at $530,809,000 after acquiring an additional 168,125 shares during the period. Institutional investors own 96.78% of the company’s stock.

Vaxcyte Company Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.